

## **Appendix**

### **Post-viral mental health sequelae: Systematic review and meta-analysis of prevalence proportions**

Simeon Joel Zürcher, Céline Banzer, Christine Adamus, Anja I. Lehmann, Dirk Richter, Philipp Kerksieck

<b>1. eTable 1:</b> PubMed search terms	2
<b>2. eTable 2:</b> PsycInfo and Embase search terms	2
<b>3. eTable 3:</b> Inclusion and exclusion criteria	3
<b>4. eTable 4:</b> Variables extracted from included studies	4
<b>5. eTable 5:</b> Cut-off values by instruments for case detection to categorize domains and severity (at least mild or at least moderate-to-severe severity)	5
<b>6. eFigure 1:</b> Summary of methodological quality appraisal of the studies included in the meta-analysis assessed by an adapted version of the Joanna Briggs Institute Critical Appraisal (JBI) tools for Prevalence Studies	6
<b>7 eTable 6:</b> Single and pooled estimates of studies on mental health prevalence rates according to domain, severity and time point	8
<b>8 eTable 7:</b> Test of moderators on mild or moderate mental health problem severity including all domains adjusted for follow-up time	14

**eTable 1:** PubMed search terms

<b>Population</b>	Betacoronavirus <i>OR</i> Sars* <i>OR</i> COVID* <i>OR</i> 2019-nCoV <i>OR</i> Corona <i>OR</i> Coronavirus <i>OR</i> "Severe Acute Respiratory" <i>OR</i> Mers* <i>OR</i> "Middle East Respiratory" <i>OR</i> H1N1 <i>OR</i> Swine-Origin Influenza <i>OR</i> "Avian Influenza" <i>OR</i> "Avian Flu" <i>OR</i> H5N1 <i>OR</i> Ebola*
<b>AND</b>	
<b>Outcomes</b>	"impact of event scale" <i>OR</i> IES <i>OR</i> IES-R <i>OR</i> "center for epidemiologic studies depression scale" <i>OR</i> CES-D <i>OR</i> CESD-R <i>OR</i> "patient health questionnaire" <i>OR</i> PHQ <i>OR</i> PHQ-D <i>OR</i> PHQ-2 <i>OR</i> PHQ-4 <i>OR</i> PHQ-7 <i>OR</i> PHQ-9 <i>OR</i> PHQ-15 <i>OR</i> "Generalized Anxiety Disorder" <i>OR</i> GAD-2 <i>OR</i> GAD-7 <i>OR</i> "hospital anxiety and depression scale" <i>OR</i> HADS <i>OR</i> "general health questionnaire" <i>OR</i> GHQ <i>OR</i> GHQ-12 <i>OR</i> GHQ-28 <i>OR</i> GHQ-30 <i>OR</i> CHQ
<b>Filter</b>	From 2002 to current (April 13, 2021)

**eTable 2:** PsycInfo and Embase search terms

<b>Population</b>	Betacoronavirus <i>or</i> Sars* <i>or</i> COVID* <i>or</i> 2019-nCoV <i>or</i> Corona <i>or</i> Coronavirus <i>or</i> "Severe Acute Respiratory" <i>or</i> Mers* <i>or</i> "Middle East Respiratory" <i>or</i> H1N1 <i>or</i> Swine-Origin Influenza <i>or</i> "Avian Influenza" <i>or</i> "Avian Flu" <i>or</i> H5N1 <i>or</i> Ebola*
<b>AND</b>	
<b>Outcomes</b>	"impact of event scale" <i>or</i> IES <i>or</i> IES-R <i>or</i> "center for epidemiologic studies depression scale" <i>or</i> CES-D <i>or</i> CESD-R <i>or</i> "patient health questionnaire" <i>or</i> PHQ <i>or</i> PHQ-D <i>or</i> PHQ-2 <i>or</i> PHQ-4 <i>or</i> PHQ-7 <i>or</i> PHQ-9 <i>or</i> PHQ-15 <i>or</i> "Generalized Anxiety Disorder" <i>or</i> GAD-2 <i>or</i> GAD-7 <i>or</i> "hospital anxiety and depression scale" <i>or</i> HADS <i>or</i> "general health questionnaire" <i>or</i> GHQ <i>or</i> GHQ-12 <i>or</i> GHQ-28 <i>or</i> GHQ-30 <i>or</i> CHQ
<b>Filter</b>	From 2002 to current (April 13, 2021)

**eTable 3:** Inclusion and exclusion criteria

<b>Population(s)</b>	<b>Include</b>	<b>Exclude</b>
	<ul style="list-style-type: none"> <li>*Patients</li> <li>*Survivors</li> <li>*Individuals with suspected infection</li> <li>*Adults (<math>\geq 18</math> yrs.)</li> </ul>	<ul style="list-style-type: none"> <li>*Health care workers</li> <li>*General population</li> <li>*Other/special populations (e.g., physical chronical illness, cancer patients, renal transplantation, pregnant women, people with mental illness)</li> <li>*Quarantined individuals (relevant outcomes, setting and characteristics is not reported for cases that test positive or suspected for a virus infection)</li> </ul>
<b>Context</b>	<b>Include</b>	<b>Exclude</b>
	<ul style="list-style-type: none"> <li>*Virus epidemics including:           <ul style="list-style-type: none"> <li>**SARS-CoV-1</li> <li>**Swine flu (H1N1)</li> <li>**MERS-CoV</li> <li>**Avian influenza (H7N9)</li> <li>**Ebola virus</li> <li>**SARS-CoV-2</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>*Other epidemics (e.g., HIV/AIDS)</li> <li>*Common influenza</li> <li>*Other context (e.g., natural disasters, occupational studies)</li> </ul>
<b>Outcome/Condition</b>	<b>Include</b>	<b>Exclude</b>
	<ul style="list-style-type: none"> <li>*Prevalence rates provided based on established cut-off scores (or possibility to calculate it) as measured by any short or long form of the following instruments:           <ul style="list-style-type: none"> <li>**Impact of Event Scale (IES)</li> <li>**The Center for Epidemiological Studies Depression Scale (CES-D)</li> <li>**The Patient Health Questionnaire (PHQ)</li> <li>**Generalized Anxiety Disorder Scale (GAD)</li> <li>**The Hospital Anxiety and Depression Scale (HADS)</li> <li>*The General Health Questionnaire (GHQ)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>*No prevalence rates provided/calculation not possible (e.g., only mean scores provided)</li> <li>*Prevalence rates assessed by other instruments (e.g., BAI, DASS)</li> <li>*Prevalence rates not based on established cut-off scores (e.g., data-driven cut-off scores like median grouping)</li> <li>*Provided IES prevalence rates for subscales only</li> </ul>
<b>Study design/Type</b>	<b>Include</b>	<b>Exclude</b>
	<ul style="list-style-type: none"> <li>*All studies that provide prevalence data:</li> <li>*Clinical trial/experimental (only first measure if mental health intervention took place)</li> <li>*Cross-sectional study</li> <li>*Cohort study</li> <li>*Case control study</li> <li>*Case series</li> </ul>	<ul style="list-style-type: none"> <li>*Qualitative study</li> <li>*Psychometric study/questionnaire validation</li> <li>*Editorial/Letter</li> <li>*Mini-study</li> <li>*Review</li> <li>*Conference abstract</li> <li>*Non-scientific article</li> <li>*Studies with <math>n &lt; 5</math></li> </ul>
<b>Other criteria</b>	<b>Include</b>	
	<ul style="list-style-type: none"> <li>*Languages: English, German, Spanish, Dutch or French</li> </ul>	

**eTable 4:** Variables extracted from included studies

Extracted variable	Label/unit
DOI	digital object identifier
First author	last name of first author
Year of publication	YYYY
Title of publication	full title
County	country
World region	Africa, Amerika, Asia (excluding China), China, Europe
Design	cross-sectional, longitudinal (repeated measures design), intervention study
Sampling	random or complete sample (attempt to include all eligible participants), non-random or unknown sampling strategy (e.g., convenience/snowball)
Response rate	numerator: Number of individuals included denominator: Number of eligible individuals (excluding deceased)
Epidemic	severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), swine flu (H1N1), Middle East respiratory syndrome coronavirus (MERS-CoV), avian influenza (H7N9), Ebolavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Sex	% of female sex
Age	mean or median and standard deviation
Psychological condition	percent with prior psychiatric condition including a history of psychiatric illness or condition or history of psychiatric visits
Duration of hospitalization	mean and standard deviation of hospitalization or treatment
Intensive care unit	% of included individuals in need of ICU care
Health care workers	% of individuals working in the health care sector
Education	% of individuals with higher education (tertiary education, university degree)
Treatment received	inpatient, outpatient, miscellaneous (inpatient and outpatient)
Time point of assessment	mean or median months since discharge/treatment, further coded as acute ( $\leq 1$ months), ongoing (1-3 Months), post-illness ( $> 3$ months)
Instrument	IES, IES-R, IES-6 (short form), CES-D, CESD-R (revised), CES-D (short form), PHQ-D (full version), PHQ-9 (depression module), PHQ-2 (depression module – short form), PHQ-4 (depression and anxiety module – short form), PHQ Stress, PHQ-15 (somatization module), PHQ Panic, GAD-2 (short form), GAD-7, GHQ-12, GHQ-28, HADS anxiety, HADS depression, HADS total scale
Cut-off score	cut-off used for case detection
Number of cases	detected cases
Total number	number assessed (number of valid, non-missing responses)

**eTable 5:** Cut-off values by instruments for case detection to categorize domains and severity (at least mild or at least moderate-to-severe severity)

Assessment instrument and severity classification	Cut-off value for case classification	Severity and domain
<b>General Anxiety Disorder Scale</b>		
GAD-2 (mild)	≥1	mild anxiety
GAD-7 (mild)	≥5	mild anxiety
GAD-2 (moderate-to-severe)	≥3	moderate-to-severe anxiety
GAD-7 (moderate-to-severe)	≥10	moderate-to-severe anxiety
<b>Hospital Anxiety and Depression Scale; anxiety subscale</b>		
HADS-Anxiety (mild)	≥8	mild anxiety
HADS-Anxiety (moderate-to-severe)	≥11 (one study with ≥10)	moderate-to-severe anxiety
<b>Patient Health Questionnaire; Depression</b>		
PHQ-2 (mild)	≥1	mild depression
PHQ-9 (mild)	≥5	mild depression
PHQ-2 (moderate-to-severe)	≥3	moderate-to-severe depression
PHQ-9 (moderate-to-severe)	≥10	moderate-to-severe depression
<b>Center for Epidemiologic Studies Depression Scale</b>		
CES-D (no severity classification, indication of depression)	≥16 or >17 in males and >23 in females	moderate-to-severe depression
<b>Hospital Anxiety and Depression Scale; depression subscale</b>		
HADS-depression (mild)	≥8	mild depression
HADS-depression (moderate-to-severe)	≥11 (one study with ≥10)	moderate-to-severe depression
<b>Impact of Event Scale</b>		
IES (mild)	≥26	mild post-traumatic stress
IES-R (mild)	≥24	mild post-traumatic stress
IES (moderate-to-severe)	≥30	moderate-to-severe post-traumatic stress
IES-R (moderate-to-severe)	≥33	moderate-to-severe post-traumatic stress
IES-R (moderate-to-severe)	>2 (surpassing a mean score of 2 in all subscales)	moderate-to-severe post-traumatic stress
IES-6 (moderate-to-severe)	≥10	moderate-to-severe post-traumatic stress
<b>General Health Questionnaire</b>		
GHQ-12	3 (0-0-1-1 scoring system)	moderate-to-severe general distress
GHQ-28	24 (0-1-2-3 Likert scale scoring)	moderate-to-severe general distress
GHQ-28	≥ 5 (0-0-1-1 scoring system)	moderate-to-severe general distress
<b>Hospital Anxiety and Depression Scale; Total scale</b>		
HADS-anxiety and depression (total scale)	>16	mild anxiety and/or depression
<b>Patient Health Questionnaire; somatization module</b>		
PHQ-15 somatization (mild)	≥5	mild somatization
PHQ-15 somatization (moderate-to-severe)	≥10	moderate-to-severe somatization

**eFigure 1:** Summary of methodological quality appraisal of the studies included in the meta-analysis assessed by an adapted version of the Joanna Briggs Institute Critical Appraisal (JBI) tools for Prevalence Studies

Author & Year	Quality Item							
	Sample frame	Sampling method	Sample size	Subjects setting	Coverage	Procedures	Analyses	Response Rate
Akinci and Basar (2021)	?	✗	✗	✗	?	✓	✓	?
Bah et al. (2020)	✗	✗	✗	✗	✓	✗	✓	✓
Bellan et al. (2021)	✓	✓	✓	✓	✓	✓	✓	✓
Bonazza et al. (2020)	✓	✓	✓	✓	?	✓	✓	?
Chen et al. (2021)	?	?	✓	✗	✓	✓	✗	✓
Chen et al. (2020)	?	?	✗	✗	✓	✗	✓	?
Cheng et al. (2004)	?	?	✗	✗	✓	✓	✓	✓
Chieffo et al. (2020)	?	?	✗	✓	?	✓	✓	?
D'Cruz et al. (2021)	✓	✓	✓	✓	✓	?	✓	✓
Etard et al. (2017)	✓	✓	✓	✓	✓	✓	✓	✓
Guo et al. (2020)	?	?	✗	✓	✓	✓	✗	?
He et al. (2021)	?	?	✗	✓	✓	✓	✓	✗
Heyns et al. (2021)	✓	✓	✓	✓	✓	✓	✓	✗
Horn et al. (2020)	✓	✓	✓	✓	✓	✓	✗	✓
Hu et al. (2020)	?	?	✗	✓	✓	✗	✓	✗
Islam et al. (2021)	✗	✗	✓	✗	✗	✓	✓	✓
Jeong et al. (2016)	✓	✗	✗	✗	✓	✓	✓	✗
Jeong et al. (2020)	?	?	✗	✓	✓	✓	✓	?
Ju et al. (2021)	✓	✓	✓	✓	?	✓	?	✗
Kandeger et al. (2020)	✓	✓	✓	✗	✓	✓	✗	✗
Kang et al. (2020)	✓	✓	✓	✗	✓	✓	✗	✓
Keita et al. (2017)	✓	✓	✓	✓	✓	✓	✓	✗
Kim et al. (2018)	✓	✓	✓	✓	✓	✓	✓	✗
Kim et al. (2020)	✓	✓	✓	✗	?	✓	✓	✗
Kong et al. (2020)	?	?	✗	✗	✓	✓	✓	✓
Kwek et al. (2006)	?	✓	?	✓	✗	?	✓	✓
Lam et al. (2009)	✓	✓	✓	✗	?	✓	✗	✗
Lee et al. (2007)	?	?	?	✗	?	✓	✓	✓
Lee et al. (2019)	✓	✓	✓	✓	?	✓	✓	✓
Li et al. (2020)	?	?	✗	✗	✓	?	✓	✗
Luyt et al. (2012)	✓	✓	✓	✓	✓	?	✓	✓
Ma et al. (2020)	?	?	✓	?	✓	✓	✓	✓
Mak et al. (2009)	✓	✓	✓	✓	✓	✓	✓	✓
Martillo et al. (2021)	✓	✓	✓	✓	✗	✓	✓	✗
Mazza et al. (2020)	?	?	?	✓	✓	✓	✓	✗
Mina et al. (2021)	✗	✗	✗	✗	✗	✓	✓	✗

**eFigure 1:** Continued

Author & Year	Quality Item								
	Sample frame	Sampling method	Sample size	Subjects setting	Coverage	Procedures	Analyses	Response Rate	
Morin et al. (2021)	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mowla et al. (2021)	✓	✓	✓	✗	✗	✓	✓	✓	✓
Olanipekun et al. (2021)	✓	✓	✓	✓	✗	✓	✓	✓	✓
Park et al. (2020)	✓	✓	✓	✓	✓	?	✓	✓	✗
Parker et al. (2021)	✓	✓	✓	✓	✗	✓	✓	✓	✗
Paz et al. (2020)	✗	?	✓	✗	✓	✓	✓	✓	✗
Poyraz et al. (2021)	✓	✓	✓	✓	✗	✗	✓	✓	✗
Raman et al. (2021)	✓	✓	✓	✓	✓	✓	✓	✓	✗
Rass et al. (2021)	✓	✓	✓	✓	✓	?	✓	✓	✓
Sahan et al. (2021)	✓	✓	✓	✓	✓	✓	✓	✓	✓
Samrah et al. (2020)	✓	✓	✓	✓	✓	✓	✓	✓	✓
Secor et al. (2020)	✓	✓	✓	✗	?	✓	✓	✓	?
Sheng et al. (2005)	?	?	✗	✓	✗	✓	✓	✓	?
Speth et al. (2020)	✓	✓	✓	✗	✓	?	✓	✓	✗
van den Borst et al. (2020)	✓	✓	✓	✓	✓	?	✓	✓	✓
Wang et al. (2021)	✓	✓	✓	✗	✗	✓	✓	✓	✓
Wu et al. (2005a)	✓	✓	✓	✓	✓	✓	✓	✓	✗
Wu et al. (2005b)	?	?	?	✗	✓	✓	✓	✓	✓
Xu et al. (2021)	✓	?	?	✗	✓	✓	✓	✓	?
Yadav et al. (2021)	?	?	?	✓	✗	?	✓	✓	✗
Zarghami et al. (2020)	✓	✓	✓	✓	?	✓	✗	✓	✗
Zhang et al. (2020a)	?	✗	✗	✓	✓	✓	✓	✓	?
Zhang et al. (2020b)	✗	✗	✓	✗	✓	✓	✓	✓	?

✓ =yes; ✗ =no; ? =unclear

Sample frame=was the sample frame appropriate to assess the target population? Sampling=were the study participants selected/recruited in an appropriate way? Sample size=was the sample size adequate? Subjects Setting=were the study subjects and setting described in detail? Coverage=was data analysis conducted with sufficient coverage of the identified sample? Procedures=was the condition measured in a standardized, reliable way for all participants? Analyses=was there appropriate statistical analysis? Response rate=was the response rate adequate, and if not, was the low response rate managed appropriately?

**eTable 6:** Single and pooled estimates of studies on mental health prevalence rates according to domain, severity and timepoint

Severity, Domain, Timepoint First author	Year	Country	Epidemic	No. of cases	Sample size	Pooled prevalence (95% CI)
<b>Mild anxiety, acute</b>						
Chen et al.	2020	China	SARS-CoV-2	6	31	19·4 (7·0-35·4)
Guo et al.	2020	China	SARS-CoV-2	57	103	55·3 (45·6-64·9)
He et al.	2021	China	SARS-CoV-2	34	65	52·3 (40·1-64·4)
Heyns et al.	2021	Belgium	SARS-CoV-2	16	47	34·0 (21·1-48·3)
Hu et al.	2020	China	SARS-CoV-2	33	85	38·8 (28·7-49·5)
Ju et al.	2021	China	SARS-CoV-2	41	95	43·2 (33·3-53·3)
Ju et al.	2021	China	SARS-CoV-2	36	95	37·9 (28·4-47·9)
Kang et al.	2020	South Korea	SARS-CoV-2	16	107	15·0 (8·8-22·4)
Kim et al.	2020	South Korea	SARS-CoV-2	6	33	18·2 (6·6-33·4)
Kong et al.	2020	China	SARS-CoV-2	50	144	34·7 (27·1-42·7)
Li et al.	2020	China	SARS-CoV-2	41	99	41·4 (31·9-51·3)
Mina et al.	2021	Bangladesh	SARS-CoV-2	92	145	63·4 (55·4-71·1)
Park et al.	2020	South Korea	MERS-CoV	44	63	69·8 (57·9-80·6)
Parker et al.	2021	USA	SARS-CoV-2	21	58	36·2 (24·3-49·1)
Paz et al.	2020	Ecuador	SARS-CoV-2	441	759	58·1 (54·6-61·6)
Speth et al.	2020	Switzerland	SARS-CoV-2	51	114	44·7 (35·7-54·0)
Wang et al.	2021	China	SARS-CoV-2	213	460	46·3 (41·8-50·9)
Yadav et al.	2021	India	SARS-CoV-2	67	100	67·0 (57·4-75·9)
Zarghami et al.	2020	Iran	SARS-CoV-2	7	30	23·3 (9·7-40·4)
Zarghami et al.	2020	Iran	SARS-CoV-2	17	52	32·7 (20·5-46·1)
Zhang et al.	2020a	China	SARS-CoV-2	30	30	100·0 (94·3-100·0)
Zhang et al.	2020b	China	SARS-CoV-2	62	296	20·9 (16·5-25·8)
<b>Summary Effect</b>				<b>1381</b>	<b>3011</b>	<b>44·7 (34·0-55·6)</b>
<b>Mild anxiety, ongoing</b>						
Bonazza et al.	2020	Italy	SARS-CoV-2	73	261	28·0 (22·7-33·6)
Kwek et al.	2006	Singapore	SARS-CoV-1	21	63	33·3 (22·2-45·5)
Raman et al.	2021	UK	SARS-CoV-2	22	57	38·6 (26·3-51·6)
Rass et al.	2021	Austria	SARS-CoV-2	17	98	17·3 (10·4-25·5)
<b>Summary Effect</b>				<b>133</b>	<b>479</b>	<b>28·3 (20·0-37·5)</b>
<b>Mild anxiety, post-illness</b>						
Bah et al.	2020	Sierra Leone	Ebolavirus	49	197	24·9 (19·1-31·2)
Luyt et al.	2012	France	H1N1	20	37	54·1 (37·7-69·9)
Morin et al.	2021	France	SARS-CoV-2	53	169	31·4 (24·6-38·6)
Park et al.	2020	South Korea	MERS-CoV	20	63	31·7 (20·8-43·8)
Secor et al.	2020	Liberia	Ebolavirus	74	203	36·5 (30·0-43·2)
Secor et al.	2020	Sierra Leone	Ebolavirus	317	751	42·2 (38·7-45·8)
Secor et al.	2020	Guinea	Ebolavirus	120	530	22·6 (19·2-26·3)
<b>Summary Effect</b>				<b>653</b>	<b>1950</b>	<b>33·5 (24·8-42·7)</b>

**eTable 6:** Continued

Severity, Domain, Timepoint First author	Year	Country	Epidemic	No. of cases	Sample size	Pooled prevalence (95% CI)
<b>Moderate-to-severe anxiety, acute</b>						
Akinici and Basar	2021	Turkey	SARS-CoV-2	25	189	13·2 (8·7-18·5)
Chen et al.	2021	China	SARS-CoV-2	147	898	16·4 (14·0-18·9)
Chen et al.	2020	China	SARS-CoV-2	3	31	9·7 (1·3-23·1)
Guo et al.	2020	China	SARS-CoV-2	7	103	6·8 (2·6-12·6)
He et al.	2021	China	SARS-CoV-2	10	65	15·4 (7·5-25·3)
Hu et al.	2020	China	SARS-CoV-2	14	85	16·5 (9·3-25·2)
Jeong et al.	2016	South Korea	MERS-CoV	17	36	47·2 (31·0-63·7)
Jeong et al.	2020	South Korea	SARS-CoV-2	13	126	10·3 (5·5-16·3)
Ju et al.	2021	China	SARS-CoV-2	16	95	16·8 (9·9-25·1)
Ju et al.	2021	China	SARS-CoV-2	11	95	11·6 (5·8-18·9)
Kandeger et al.	2020	Turkey	SARS-CoV-2	16	84	19·0 (11·3-28·2)
Kang et al.	2020	South Korea	SARS-CoV-2	2	107	1·9 (0·0-5·6)
Kong et al.	2020	China	SARS-CoV-2	25	144	17·4 (11·6-24·0)
Li et al.	2020	China	SARS-CoV-2	15	99	15·2 (8·7-23·0)
Mina et al.	2021	Bangladesh	SARS-CoV-2	38	145	26·2 (19·3-33·7)
Mina et al.	2021	Bangladesh	SARS-CoV-2	42	145	29·0 (21·8-36·6)
Park et al.	2020	South Korea	MERS-CoV	33	63	52·4 (40·0-64·7)
Parker et al.	2021	USA	SARS-CoV-2	8	58	13·8 (5·9-24·0)
Paz et al.	2020	Ecuador	SARS-CoV-2	171	759	22·5 (19·6-25·6)
Sahan et al.	2021	Turkey	SARS-CoV-2	98	281	34·9 (29·4-40·6)
Speth et al.	2020	Switzerland	SARS-CoV-2	12	114	10·5 (5·5-16·9)
Wang et al.	2021	China	SARS-CoV-2	91	460	19·8 (16·3-23·6)
Wu et al.	2005a	China	SARS-CoV-1	28	195	14·4 (9·8-19·7)
Wu et al.	2005b	China	SARS-CoV-1	17	131	13·0 (7·7-19·3)
Yadav et al.	2021	India	SARS-CoV-2	13	100	13·0 (7·0-20·4)
Zhang et al.	2020a	China	SARS-CoV-2	23	30	76·7 (59·6-90·3)
<b>Summary Effect</b>				<b>895</b>	<b>4638</b>	<b>19·2 (13·5-25·7)</b>
<b>Moderate-to-severe anxiety, ongoing</b>						
Bonazza et al.	2020	Italy	SARS-CoV-2	35	261	13·4 (9·5-17·8)
D'Cruz et al.	2021	UK	SARS-CoV-2	25	113	22·1 (14·9-30·3)
Kwek et al.	2006	Singapore	SARS-CoV-1	11	63	17·5 (9·0-27·9)
Poyraz et al.	2021	Turkey	SARS-CoV-2	50	284	17·6 (13·4-22·3)
Raman et al.	2021	UK	SARS-CoV-2	8	57	14·0 (6·0-24·4)
Rass et al.	2021	Austria	SARS-CoV-2	7	98	7·1 (2·7-13·2)
van den Borst et al.	2020	Netherlands	SARS-CoV-2	12	124	9·7 (5·0-15·6)
Wu et al.	2005b	China	SARS-CoV-1	18	131	13·7 (8·3-20·2)
<b>Summary Effect</b>				<b>166</b>	<b>1131</b>	<b>14·1 (11·1-17·5)</b>

**eTable 6:** Continued

Severity, Domain, Timepoint First author	Year	Country	Epidemic	No. of cases	Sample size	Pooled prevalence (95% CI)
<b>Moderate-to-severe anxiety, post-illness</b>						
Jeong et al.	2016	South Korea	MERS-CoV	7	36	19·4 (7·9-34·2)
Mak et al.	2009	China	SARS-CoV-1	14	90	15·6 (8·7-23·9)
Park et al.	2020	South Korea	MERS-CoV	9	63	14·3 (6·6-24·1)
Secor et al.	2020	Liberia	Ebolavirus	20	203	9·9 (6·1-14·4)
Secor et al.	2020	Sierra Leone	Ebolavirus	80	751	10·7 (8·5-13·0)
Secor et al.	2020	Guinea	Ebolavirus	22	530	4·2 (2·6-6·0)
<b>Summary Effect</b>				<b>152</b>	<b>1673</b>	<b>12·1 (5·3-21·1)</b>
<b>Mild depression, acute</b>						
Akinci and Basar	2021	Turkey	SARS-CoV-2	82	189	43·4 (36·4-50·5)
Chen et al.	2020	China	SARS-CoV-2	10	31	32·3 (16·8-49·9)
Guo et al.	2020	China	SARS-CoV-2	62	103	60·2 (50·5-69·5)
He et al.	2021	China	SARS-CoV-2	31	65	47·7 (35·6-59·9)
Heyns et al.	2021	Belgium	SARS-CoV-2	16	47	34·0 (21·1-48·3)
Hu et al.	2020	China	SARS-CoV-2	39	85	45·9 (35·4-56·6)
Islam et al.	2021	Bangladesh	SARS-CoV-2	698	1002	69·7 (66·8-72·5)
Ju et al.	2021	China	SARS-CoV-2	38	95	40·0 (30·3-50·1)
Ju et al.	2021	China	SARS-CoV-2	29	95	30·5 (21·6-40·2)
Kandeger et al.	2020	Turkey	SARS-CoV-2	29	84	34·5 (24·7-45·1)
Kang et al.	2020	South Korea	SARS-CoV-2	26	107	24·3 (16·6-32·9)
Kim et al.	2018	South Korea	MERS-CoV	11	27	40·7 (22·8-60·0)
Kim et al.	2020	South Korea	SARS-CoV-2	13	33	39·4 (23·3-56·7)
Kong et al.	2020	China	SARS-CoV-2	41	144	28·5 (21·4-36·1)
Li et al.	2020	China	SARS-CoV-2	50	99	50·5 (40·6-60·4)
Ma et al.	2020	China	SARS-CoV-2	332	770	43·1 (39·6-46·6)
Martillo et al.	2021	USA	SARS-CoV-2	17	42	40·5 (26·0-55·8)
Mina et al.	2021	Bangladesh	SARS-CoV-2	82	145	56·6 (48·4-64·5)
Park et al.	2020	South Korea	MERS-CoV	50	63	79·4 (68·4-88·6)
Parker et al.	2021	USA	SARS-CoV-2	17	58	29·3 (18·2-41·8)
Paz et al.	2020	Ecuador	SARS-CoV-2	399	759	52·6 (49·0-56·1)
Sahan et al.	2021	Turkey	SARS-CoV-2	118	281	42·0 (36·3-47·8)
Samrah et al.	2020	Jordan	SARS-CoV-2	29	66	43·9 (32·1-56·1)
Speth et al.	2020	Switzerland	SARS-CoV-2	54	114	47·4 (38·2-56·6)
Wang et al.	2021	China	SARS-CoV-2	246	460	53·5 (48·9-58·0)
Yadav et al.	2021	India	SARS-CoV-2	27	100	27·0 (18·7-36·2)
Zarghami et al.	2020	Iran	SARS-CoV-2	13	30	43·3 (26·0-61·5)
Zarghami et al.	2020	Iran	SARS-CoV-2	18	52	34·6 (22·2-48·2)
Zhang et al.	2020a	China	SARS-CoV-2	30	30	100·0 (94·3-100·0)
Zhang et al.	2020b	China	SARS-CoV-2	55	296	18·6 (14·3-23·2)
<b>Summary Effect</b>				<b>2662</b>	<b>5472</b>	<b>45·3 (38·0-52·7)</b>

**eTable 6:** Continued

Severity, Domain, Timepoint First author	Year	Country	Epidemic	No. of cases	Sample size	Pooled prevalence (95% CI)
<b>Mild depression, ongoing</b>						
Bonazza et al.	2020	Italy	SARS-CoV-2	44	261	16·9 (12·5-21·7)
Kwek et al.	2006	Singapore	SARS-CoV-1	17	63	27·0 (16·7-38·7)
Olanipekun et al.	2021	USA	SARS-CoV-2	51	73	69·9 (58·8-79·9)
Raman et al.	2021	UK	SARS-CoV-2	24	57	42·1 (29·5-55·2)
Rass et al.	2021	Austria	SARS-CoV-2	8	98	8·2 (3·4-14·5)
<b>Summary Effect</b>				<b>144</b>	<b>552</b>	<b>30·8 (11·7-54·1)</b>
<b>Mild depression, post-illness</b>						
Bah et al.	2020	Sierra Leone	Ebolavirus	93	197	47·2 (40·3-54·2)
Luyt et al.	2012	France	H1N1	10	37	27·0 (13·8-42·6)
Park et al.	2020	South Korea	MERS-CoV	35	63	55·6 (43·1-67·7)
Secor et al.	2020	Liberia	Ebolavirus	96	198	48·5 (41·5-55·5)
Secor et al.	2020	Sierra Leone	Ebolavirus	350	751	46·6 (43·0-50·2)
Secor et al.	2020	Guinea	Ebolavirus	178	529	33·6 (29·7-37·7)
<b>Summary Effect</b>				<b>762</b>	<b>1775</b>	<b>43·5 (34·1-53·1)</b>
<b>Moderate-to-severe depression, acute</b>						
Chen et al..	2021	China	SARS-CoV-2	189	898	21·0 (18·4-23·8)
Chen et al.	2020	China	SARS-CoV-2	2	31	6·5 (0·1-18·5)
Guo et al.	2020	China	SARS-CoV-2	18	103	17·5 (10·7-25·5)
He et al.	2021	China	SARS-CoV-2	18	65	27·7 (17·4-39·3)
Hu et al.	2020	China	SARS-CoV-2	21	85	24·7 (16·1-34·5)
Islam et al.	2021	Bangladesh	SARS-CoV-2	482	1002	48·1 (45·0-51·2)
Jeong et al.	2020	South Korea	SARS-CoV-2	20	126	15·9 (10·0-22·8)
Ju et al.	2021	China	SARS-CoV-2	17	95	17·9 (10·8-26·3)
Ju et al.	2021	China	SARS-CoV-2	13	95	13·7 (7·4-21·4)
Kang et al.	2020	South Korea	SARS-CoV-2	7	107	6·5 (2·5-12·1)
Kim et al.	2018	South Korea	MERS-CoV	3	27	11·1 (1·5-26·3)
Kong et al.	2020	China	SARS-CoV-2	21	144	14·6 (9·2-20·9)
Li et al.	2020	China	SARS-CoV-2	29	99	29·3 (20·7-38·7)
Ma et al.	2020	China	SARS-CoV-2	143	770	18·6 (15·9-21·4)
Martillo et al.	2021	USA	SARS-CoV-2	8	42	19·0 (8·4-32·5)
Park et al.	2020	South Korea	MERS-CoV	42	63	66·7 (54·5-77·8)
Parker et al.	2021	USA	SARS-CoV-2	12	58	20·7 (11·1-32·2)
Paz et al.	2020	Ecuador	SARS-CoV-2	154	759	20·3 (17·5-23·2)
Samrah et al.	2020	Jordan	SARS-CoV-2	14	66	21·2 (12·1-32·0)
Speth et al.	2020	Switzerland	SARS-CoV-2	24	114	21·1 (14·0-29·1)
Wang et al.	2021	China	SARS-CoV-2	114	460	24·8 (20·9-28·8)
Wu et al.	2005a	China	SARS-CoV-1	35	195	17·9 (12·9-23·7)
Wu et al.	2005b	China	SARS-CoV-1	23	131	17·6 (11·5-24·6)
Xu et al.	2021	China	SARS-CoV-2	12	121	9·9 (5·1-16·0)
Yadav et al.	2021	India	SARS-CoV-2	6	100	6·0 (2·0-11·6)
Zhang et al.	2020a	China	SARS-CoV-2	23	30	76·7 (59·6-90·3)
<b>Summary Effect</b>				<b>1450</b>	<b>5786</b>	<b>21·9 (15·8-28·6)</b>

**eTable 6:** Continued

Severity, Domain, Timepoint First author	Year	Country	Epidemic	No. of cases	Sample size	Pooled prevalence (95% CI)
<b>Moderate-to-severe depression, ongoing</b>						
Bonazza et al.	2020	Italy	SARS-CoV-2	27	261	10·3 (6·9-14·4)
D'Cruz et al.	2021	UK	SARS-CoV-2	20	111	18·0 (11·4-25·8)
Kwek et al.	2006	Singapore	SARS-CoV-1	7	63	11·1 (4·3-20·2)
Olanipekun et al.	2021	USA	SARS-CoV-2	40	73	54·8 (43·2-66·1)
Poyraz et al.	2021	Turkey	SARS-CoV-2	51	284	18·0 (13·7-22·7)
Raman et al.	2021	UK	SARS-CoV-2	11	57	19·3 (10·0-30·7)
Rass et al.	2021	Austria	SARS-CoV-2	3	98	3·1 (0·4-7·6)
van den Borst et al.	2020	Netherlands	SARS-CoV-2	14	124	11·3 (6·2-17·5)
Wu et al.	2005b	China	SARS-CoV-1	17	131	13·0 (7·7-19·3)
<b>Summary Effect</b>				<b>190</b>	<b>1202</b>	<b>16·0 (8·6-25·2)</b>
<b>Moderate-to-severe depression, post-illness</b>						
Etard et al.	2017	Guinea	Ebolavirus	97	472	20·6 (17·0-24·3)
Keita et al.	2017	Guinea	Ebolavirus	38	256	14·8 (10·7-19·5)
Lee et al.	2019	South Korea	MERS-CoV	14	52	26·9 (15·6-39·9)
Lee et al.	2019	South Korea	MERS-CoV	9	52	17·3 (8·1-28·9)
Mak et al.	2009	China	SARS-CoV-1	17	90	18·9 (11·4-27·7)
Park et al.	2020	South Korea	MERS-CoV	17	63	27·0 (16·7-38·7)
Secor et al.	2020	Liberia	Ebolavirus	43	198	21·7 (16·2-27·8)
Secor et al.	2020	Sierra Leone	Ebolavirus	136	751	18·1 (15·4-20·9)
Secor et al.	2020	Guinea	Ebolavirus	49	529	9·3 (6·9-11·9)
<b>Summary Effect</b>				<b>420</b>	<b>2463</b>	<b>18·2 (13·8-23·0)</b>
<b>Mild post-traumatic stress, acute</b>						
Bellan et al.	2021	Italy	SARS-CoV-2	102	238	42·9 (36·6-49·2)
Chieffo et al.	2020	Italy	SARS-CoV-2	27	33	81·8 (66·6-93·4)
<b>Summary Effect</b>				<b>129</b>	<b>271</b>	<b>62·4 (23·6-93·8)</b>
<b>Mild post-traumatic stress, ongoing</b>						
Kwek et al.	2006	Singapore	SARS-CoV-1	26	63	41·3 (29·4-53·7)
Poyraz et al.	2021	Turkey	SARS-CoV-2	124	284	43·7 (37·9-49·5)
<b>Summary Effect</b>				<b>150</b>	<b>347</b>	<b>43·2 (38·0-48·5)</b>
<b>Mild post-traumatic stress, post-illness</b>						
Chieffo et al.	2020	Italy	SARS-CoV-2	7	14	50·0 (23·7-76·3)
Lee et al.	2019	South Korea	MERS-CoV	22	52	42·3 (29·1-56·0)
Lee et al.	2019	South Korea	MERS-CoV	14	52	26·9 (15·6-39·9)
Park et al.	2020	South Korea	MERS-CoV	27	63	42·9 (30·8-55·3)
<b>Summary Effect</b>				<b>70</b>	<b>181</b>	<b>38·6 (24·0-54·3)</b>

**eTable 6:** Continued

Severity, Domain, Timepoint First author	Year	Country	Epidemic	No. of cases	Sample size	Pooled prevalence (95% CI)
<b>Moderate-to-severe post-traumatic stress, acute</b>						
Bellan et al.	2021	Italy	SARS-CoV-2	41	238	17·2 (12·7-22·3)
Chieffo et al.	2020	Italy	SARS-CoV-2	19	33	57·6 (40·2-74·1)
Horn et al.	2020	France	SARS-CoV-2	60	179	33·5 (26·8-40·6)
Mazza et al.	2020	Italy	SARS-CoV-2	71	300	23·7 (19·0-28·7)
Mazza et al.	2020	Italy	SARS-CoV-2	34	102	33·3 (24·5-42·8)
Wu et al.	2005a	China	SARS-CoV-1	11	195	5·6 (2·8-9·4)
Wu et al.	2005b	China	SARS-CoV-1	6	131	4·6 (1·5-8·9)
<b>Summary Effect</b>				<b>242</b>	<b>1178</b>	<b>25·3 (7·5-48·9)</b>
<b>Moderate-to-severe post-traumatic stress, ongoing</b>						
Bonazza et al.	2020	Italy	SARS-CoV-2	67	184	36·4 (29·6-43·5)
Kwek et al.	2006	Singapore	SARS-CoV-1	23	63	36·5 (25·0-48·8)
Poyraz et al.	2021	Turkey	SARS-CoV-2	72	284	25·4 (20·5-30·6)
van den Borst et al.	2020	Netherlands	SARS-CoV-2	12	122	9·8 (5·1-15·8)
Wu et al.	2005b	China	SARS-CoV-1	7	131	5·3 (2·0-10·0)
<b>Summary Effect</b>				<b>181</b>	<b>784</b>	<b>20·9 (9·2-35·7)</b>
<b>Moderate-to-severe post-traumatic stress, post-illness</b>						
Chieffo et al.	2020	Italy	SARS-CoV-2	4	14	28·6 (7·4-55·4)
Luyt et al.	2012	France	H1N1	16	37	43·2 (27·6-59·6)
<b>Summary Effect</b>				<b>20</b>	<b>51</b>	<b>39·1 (25·7-53·2)</b>
<b>Moderate-to-severe general distress, ongoing</b>						
Cheng et al.	2004	China	SARS-CoV-1	68	100	68·0 (58·5-76·8)
Sheng et al.	2005	China	SARS-CoV-1	66	102	64·7 (55·1-73·7)
<b>Summary Effect</b>				<b>134</b>	<b>202</b>	<b>66·3 (59·6-72·7)</b>
<b>Single prevalence rates (no pooling)</b>						
Wang et al. (mild somatization, acute)	2021	China	SARS-CoV-2	304	460	66·1 (61·7-70·3)
Mowla et al. (moderate general distress, acute)	2021	Iran	SARS-CoV-2	69	69	100·0 (97·5-100·0)
Wang et al. (moderate somatization, acute)	2021	China	SARS-CoV-2	167	460	36·3 (32·0-40·8)
Lam et al. (depression and anxiety jointly, post-illness)	2009	China	SARS-CoV-1	83	170	48·8 (41·3-56·4)
Lee et al. (moderate general distress, post-illness)	2007	China	SARS-CoV-1	61	96	63·5 (53·6-72·9)

**eTable 7:** Test of moderators on mild or moderate mental health problems including all domains. All moderators were tested separately and adjusted for follow-up time in months

Moderator variable	Mild mental health problems		Moderate mental health problems	
	Coefficient <sub>arcsine</sub> (95% CI)	p-value	Coefficient <sub>arcsine</sub> (95% CI)	p-value
Proportion of females	0·001 (-0·005 to 0·006)	0·7390	<0·000 (-0·005 to 0·004)	0·8835
Mean/median (years)	-0·007 (-0·014 to 0·001)	0·0926	-0·001 (-0·007 to 0·005)	0·7696
Proportion with higher education	-0·004 (-0·008 to 0·001)	0·1023	-0·002 (-0·006 to 0·003)	0·4891
Proportion with previous mental health condition	-0·005 (-0·016 to 0·006)	0·3292	0·003 (-0·006 to 0·013)	0·5027
Proportion of health care workers	-0·007 (-0·019 to 0·005)	0·2425	-0·004 (-0·014 to 0·006)	0·4457
Duration of hospitalization (days)	0·010 (-0·007 to 0·026)	0·2427	0·007 (-0·004 to 0·018)	0·2066
Proportion with intensive care unit treatment	0·000 (-0·004 to 0·004)	0·9523	0·002 (-0·001 to 0·005)	0·1456
Type of treatment				
Inpatient treatment	reference		reference	
Miscellaneous	-0·022 (-0·232 to 0·188)	0·8349	-0·072 (-0·217 to 0·072)	0·3227
Outpatient	-0·018 (-0·252 to 0·217)	0·8821	0·021 (-0·174 to 0·216)	0·8301
Response rate (%)	0·000 (-0·003 to 0·002)	0·8243	0·000 (-0·002 to 0·003)	0·8859
Sampling				
Non-random	reference		reference	
Random	-0·161 (-0·280 to -0·043)	0·0083	-0·015 (-0·095 to 0·065)	0·7122
World region				
China	reference		reference	
Other Asia	-0·066 (-0·235 to 0·103)	0·4366	0·023 (-0·110 to 0·157)	0·7284
Europe	-0·112 (-0·276 to 0·051)	0·1753	0·013 (-0·110 to 0·137)	0·8309
Africa	0·047 (-0·296 to 0·390)	0·7869	0·046 (-0·188 to 0·281)	0·6955
America	-0·007 (-0·246 to 0·232)	0·9531	0·068 (-0·126 to 0·262)	0·4905
Epidemic				
SARS-CoV-2	reference		reference	
SARS-CoV-1	0·231 (-0·146 to 0·608)	0·2260	0·067 (-0·141 to 0·275)	0·5252
MERS-CoV	0·102 (-0·169 to 0·372)	0·4568	0·145 (-0·038 to 0·329)	0·1183
Ebolavirus	0·229 (-0·158 to 0·616)	0·2424	0·113 (-0·123 to 0·349)	0·3458
H1N1	0·116 (-0·336 to 0·568)	0·6097	0·392 (0·003 to 0·782)	0·0483
Timepoint of follow-up				
Acute	Reference		Reference	
Mild	-0·130 (-0·305 to 0·045)	0·1432	-0·044 (-0·135 to 0·047)	0·3379
Post-illness	-0·184 (-0·307 to -0·061)	0·0038	-0·146 (-0·253 to -0·039)	0·0080

Shown are coefficients for a meta-regression model including arcsine transformed proportions. In categorical moderators the coefficients indicate the comparison between a respective factor level and the reference group. H1N1=Swine flu. MERS-CoV=Middle East respiratory syndrome coronavirus. SARS-CoV-1=Severe acute respiratory syndrome coronavirus 1. SARS-CoV-2=Severe acute respiratory syndrome coronavirus 2. All moderators were tested separately adjusted for follow-up time in month. A moderator analysis including all moderators jointly was not possible due to the substantial number of missing information across the studies.